1 / 19

Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus. Aetiology, Pathogenesis, History, and Treatment. The Diabetes Mellitus epidemic. Estimated 180 million people in the world have DM. That’s roughly 6% of the world population. These numbers are estimated to double by 2030.

warrick
Télécharger la présentation

Type 2 Diabetes Mellitus

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Type 2 Diabetes Mellitus Aetiology, Pathogenesis, History, and Treatment

  2. The Diabetes Mellitus epidemic • Estimated 180 million people in the world have DM. That’s roughly 6% of the world population. • These numbers are estimated to double by 2030. • Healthcare costs approaching 92 billion a year for the U.S.

  3. What is Diabetes Mellitus? • A metabolic disorder that results when the body is unable to maintain adequate insulin secretion to prevent hyperglycemia. • Disease classification: Type 1 or Type 2 • 90% of DM cases are Type 2

  4. Type 2 DM • Inception of disease begins with development of key metabolic abnormality, insulin resistance. • Integral to understanding of type 2 DM is the role of insulin/glucose in the metabolic system.

  5. Insulin • A polypeptide hormone secreted by the islet of Langerhans in β-cells of the pancreas. • First isolated in 1921 by Canadian researchers Banting & Best • Essential in homeostatic regulation of blood glucose

  6. Insulin’s function • Standard metaphor (Lock & Key) Insulin (the key) must be bound to target cell (the lock) in order for glucose to enter the target cell from the bloodstream. • Homeostatic function Signals muscle/adipose tissues and liver to absorb glucose and utilize it. When energy requirements are met, insulin in the bloodstream triggers the liver to absorb glucose and convert it into energy saving form glycogen.

  7. Insulin Resistance • Metabolic abnormality that triggers the onset of type 2 DM Normal amount of insulin becomes inadequate for proper absorption of blood glucose The body’s energy absorption system becomes inept • Hypothesized triggers of IR 1 in 10 people have genetic code for IR. Obesity, Aging, Genetics, Diet high in sucrose/HFCS

  8. Complications Vascular problems (neuropathy, nephropathy, retinopathy) Cardiovascular disease Wound infection Symptoms Frequent urination (polyuria) Frequent thirst (polydipsia) Excessive hunger (polyphagia) Ensuing Hyperglycemia

  9. Type 2 DM Diagnosis Fasting blood glucose level - diabetes is diagnosed if higher than 126 mg/dL on two occasions. Random (non-fasting) blood glucose level - diabetes is suspected if higher than 200 mg/dL and accompanied by the classic symptoms of increased thirst, urination, and fatigue. Oral glucose tolerance test - diabetes is diagnosed if glucose level is higher than 200 mg/dL after 2 hours.

  10. Treatment of type 2 DM • First goal is to eliminate symptoms and stabilize blood glucose levels. • If diet/exercise fail, then oral medications are used • Treatments include agents which increase the amount of insulin secreted by the pancreas agents which increase the sensitivity of target organs to insulin agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract.

  11. Oral Medications Overview • Sulfonylureas • Meglitinides • Biguanides • Thiazolidinediones • α-Glucosidase inhibitors • Dipeptidyl peptidase- 4 inhibitors

  12. Stimulates insulin secretion by β cells. Binds and closes K+ channels on β cells causing influx of Ca2+ which triggers the release of insulin. Not glucose dependent. Cause insulin release regardless of glucose level 1st generation Acetohexamide Chlorpropamide Tolbutamide Tolazamide 2nd generation Glipizide Gliclazide Glyburide Glimepiride Sulfonylureas

  13. Also stimulates insulin secretion by β cells Similar mechanism of action to Sulfonylureas. Attaches to K+ channel at a different binding site Insulin efflux is glucose dependent. High glucose levels are needed for optimal action. Repaglinide Nateglinide Meglitinides

  14. Improves insulin’s ability to move glucose into cells (particulary in muscle tissue) Exact mechanism of action is not fully elucidated First-line medication used for treatment of type 2 DM Metformin Biguanides

  15. Thiazolidinediones • Improves insulin sensitivity (adipose tissue) • Bind to steroid hormone nuclear receptor family- peroxisome proliferator activated receptors [PPARs]- specifically PPARγ isoform. • Activated PPARγ causes the transcription of specific genes that are intimately involved in cellular metabolism. • Activated genes regulate glucose/fat metabolism and result in increased insulin sensitivity. • rosiglitazone (Avandia) pioglitazone (Actos)

  16. Prevents digestion of carbohydrates Thus, they reduce their impact on blood glucose Competitively inhibits enzymes needed for carbohydrate digestion Acarbose Miglitol α-Glucosidase inhibitors

  17. Causes increased Incretin levels Vildagliptin Sitagliptin Dipeptidyl peptidase 4 inhibitors

  18. Drug cocktails • Combination therapy is sometimes used. Two drugs combined into one tablet. • Examples include: Sulfonylurea + Metformin = Glucovance + Metformin + Thiazolidinedione = Metaglip

  19. Future of type 2 DM • Complications can be prevented through proper diet and exercise • Goal of future drug research is normalizing blood glucose and decreasing insulin resistance • Proper education is necessary. Majority of complications are caused by negligence.

More Related